In the fiscal year of 2023, Ainos Inc. experienced a notable drop in revenue, with total revenues reaching US$122,112, a stark contrast to the US$3,519,627 reported in 2022. This decrease was primarily due to a reduction in the selling price and sales volume of the Company’s COVID-19 Antigen Rapid Test Kits, as COVID-19 infections slowed down in Taiwan.
Cost of revenues also saw a decrease to US$375,845 in 2023 from US$2,114,284 in 2022, largely attributed to lower sales volume and inventory loss recognition. The gross profit for 2023 was negative US$253,733, a significant decline from the positive gross profit of US$1,405,343 in the previous year. This negative trend was driven by decreases in sales volume, selling price, and inventory loss recognition.
Total operating expenses decreased to US$12,952,663 in 2023 from US$15,381,555 in 2022, primarily due to a decrease in share-based compensation. However, operating expenses excluding certain expenses increased to US$4,813,717 in 2023 from US$4,196,981 in 2022.
Additionally, R&D expenses rose to US$7,317,388 in 2023 from US$6,845,964 in 2022. Share-based compensation expenses and depreciation and amortization expenses also increased to US$5,252,730 in 2023 compared to US$4,711,028 in the previous year.
AIMD Stock Surges 83.04% on March 8, 2024: Potential for Future Growth
On March 8, 2024, AIMD stock experienced a significant increase in price momentum, closing at $2.05. This marked a $0.93 increase since the market last closed, representing an impressive 83.04% rise. After-hours trading saw a slight decrease in the stock price, with AIMD dropping $0.03 to $2.02. It is important for investors to consider the overall trend of the stock and its potential for future growth. AIMD’s price momentum on March 8, 2024, was driven by a combination of factors such as market conditions, company performance, and investor sentiment. Investors should conduct thorough research and consider their risk tolerance before making any decisions. AIMD’s performance on March 8, 2024, showcases the potential for growth in the stock. Investors should remain cautious and monitor the stock’s movement closely to make informed decisions about their investments.
AIMD Stock Performance Analysis: Revenue Soars, Net Income Declines
On March 8, 2024, AIMD stock experienced mixed performances based on the latest financial data provided by CNN Money. The company reported a total revenue of $3.52 million for the past year, which represents a significant increase of 491.97% compared to the previous year. However, total revenue for the last quarter was reported at $24.49 thousand, indicating a decrease of 14.24% since the previous quarter.
In terms of net income, AIMD reported a loss of $14.01 million for the past year and a loss of $2.98 million for the last quarter. This represents a decrease of 260.19% in net income since the previous year and a decrease of 26.65% since the previous quarter.
Earnings per share (EPS) for AIMD also saw a decline, with a reported EPS of -$5.14 for the past year and -$0.73 for the last quarter. This represents a decrease of 99.45% in EPS since the previous year and a decrease of 25.42% since the previous quarter.
Overall, the financial performance of AIMD on March 8, 2024, reflects a mixed picture with a significant increase in total revenue compared to the previous year, but a decline in net income and EPS. Investors may want to closely monitor the company’s financial performance and future outlook to make informed decisions regarding their investment in AIMD stock.
